Citadel Advisors
ATHE

Citadel Advisors’s Alterity Therapeutics ATHE Stock Holding History

Citadel Advisors’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$202K Buy
37,597
+17,520
+87% +$76.2K ﹤0.01% 12052
2026
Q1 		$71.5K Buy
20,077
+3,266
+19% +$11.1K ﹤0.01% 12237
2025
Q4 		$51.8K Sell
16,811
-5,333
-24% -$20.4K ﹤0.01% 12018
2025
Q3 		$83.5K Buy
+22,144
New +$107K ﹤0.01% 11948
2024
Q4 		– Sell
-11,488
Closed -$15.4K – 14468
2024
Q3 		$15.4K Buy
+11,488
New +$16.9K ﹤0.01% 12968
2024
Q2 		– Sell
-18,279
Closed -$37.5K – 14212
2024
Q1 		$37.5K Buy
+18,279
New +$35.2K ﹤0.01% 12465
2022
Q2 		– Sell
-2,358
Closed -$19K – 12828
2022
Q1 		$19K Buy
+2,358
New +$19.6K ﹤0.01% 13249
2021
Q4 		– Sell
-1,176
Closed -$15K – 13760
2021
Q3 		$15K Sell
1,176
-2,622
-69% -$36.5K ﹤0.01% 13665
2021
Q2 		$49K Sell
3,798
-2,703
-42% -$36.6K ﹤0.01% 13342
2021
Q1 		$94K Buy
+6,501
New +$110K ﹤0.01% 12515
2019
Q1 		– Sell
-1,274
Closed -$16K – 9227
2018
Q4 		$16K Buy
+1,274
New +$22.1K ﹤0.01% 8815
2017
Q4 		– Sell
-1,400
Closed -$39K – 7934
2017
Q3 		$39K Buy
1,400
+193
+16% +$5.24K ﹤0.01% 7235
2017
Q2 		$28K Buy
+1,207
New +$30K ﹤0.01% 7221
2017
Q1 		– Sell
-2,328
Closed -$38K – 7412
2016
Q4 		$38K Buy
+2,328
New +$62.2K ﹤0.01% 6925
2016
Q1 		– Sell
-623
Closed -$27K – 6740
2015
Q4 		$27K Sell
623
-954
-60% -$48.5K ﹤0.01% 7733
2015
Q3 		$85K Buy
1,577
+916
+139% +$58.1K ﹤0.01% 7113
2015
Q2 		$46K Buy
+661
New +$49.7K ﹤0.01% 7698
2015
Q1 		– Sell
-353
Closed -$35K – 8499
2014
Q4 		$35K Buy
+353
New +$38.2K ﹤0.01% 7446
2014
Q3 		– Sell
-528
Closed -$72K – 8094
2014
Q2 		$72K Sell
528
-1,464
-73% -$167K ﹤0.01% 6479
2014
Q1 		$335K Buy
+1,992
New +$1.1M ﹤0.01% 4887

Other funds holding ATHE

TLCM
Twin Lakes Capital Management Redwood Shores, California $262M AUM 60.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GT
Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
PCA
Providence Capital Advisors Charlotte, North Carolina $660M AUM 17.81% 1-Year Est. Return

Citadel Advisors's ATHE Position: Q2 2026 in Review

Citadel Advisors increased its Alterity Therapeutics (ATHE) stake by 87% in Q2 2026, buying an estimated $76.2K and bringing the position to 37,597 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #12052.

Citadel Advisors first reported a position in ATHE in Q1 2014 and has held it in 20 quarters since. The position peaked at $335K in Q1 2014. 22 funds tracked by Wall St. Rank hold ATHE as of Q2 2026.

  • Citadel Advisors held 37,597 shares of Alterity Therapeutics worth $202K as of Q2 2026.
  • Citadel Advisors bought 17,520 Alterity Therapeutics shares in Q2 2026, an estimated $76.2K.
  • Alterity Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12052 holding.
  • Citadel Advisors first reported a position in Alterity Therapeutics in Q1 2014 and has held it in 20 quarters since.
  • Citadel Advisors's Alterity Therapeutics position peaked at $335K in Q1 2014.
  • 22 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.